Figure 2.

OGE sensitizes HCC cells to cisplatin. (A) The expression of PARP1 and γH2AX in HepG2 cells treated with the indicated doses of OGE was determined via Western blotting. Ratio, the relative protein level. β-actin, loading control. (B–F) HepG2 cells were pretreated or untreated (control) with OGE (200 μg/mL) for 2 h, then treated with the indicated doses of cisplatin (B), doxorubicin (C), sorafenib (D), lenvatinib (E), and gemcitabine (F) for an additional 24 h. Cell viability was determined using the MTT assay. Data are shown as the means ± SD. Two-tailed unpaired Student’s t-test (B–F). ^★★, p < 0.01.